All News

In May 2024, the first biosimilars for aflibercept were approved, which included aflibercept-jbvf (Yesafili; Biocon Biologics), known as MYL-1701P.

Pharmacists and health care providers can counsel around vitamin D supplements and natural intake to increase a child’s vitamin D consumption.

Currently, VLS-1488 is being evaluated in a phase 1/2 trial (NCT05902988) in various advanced tumors, including high-grade serous ovarian cancer (HGSOC).

The findings may offer patients treatment options beyond symptom palliation.

Lowering prescription drug costs for patients, saving taxpayers money, helping small businesses level an anti-competitive playing field: all of this is at stake.

The designation was based on results from the DESTINY-Breast06 trial, evaluating fam-trastuzumab deruxtecan-nxki (Enhertu; AstraZeneca, Daiichi Sankyo) compared with chemotherapy.

The benefits of the daratumumab-based regimen were seen in all patients, including those with high and standard cytogenic risk levels.

The findings support current recommendations for pregnant individuals or those who might become pregnant during the influenza season, specifically those with successive pregnancies.

Positive trial results laid the groundwork for the designation.

Patients exhibited improved disease-free progression with minimal adverse effects.

The weight loss drug continues to show promise in treating a variety of other conditions.

RSV vaccination could be cost-effective among adults 60 years and older, with the ability to decrease vaccine costs and sustain efficacy.

Navenibart was developed to aid treatment of hereditary angioedema (HAE) to provide swift and sustained HAE attack prevention through administration every 3 to 6 months.

Treatment for primary coenzyme Q10 (CoQ10) deficiency can include high-dose oral CoQ10 supplementation, but not all patients respond to this treatment.

Zanubrutinib demonstrated sustained responses in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

The results validate the protective benefits of the sodium–glucose cotransporter-2 inhibitors on renal function for those with type 2 diabetes.

A recent study found that indoor allergen exposure, including mouse and cockroach allergens, led to an increased risk of respiratory viral infections in children with asthma.

The accelerated course was safe and effective and did not increase complications in patients with breast cancer post-mastectomy undergoing breast reconstruction.

The AHA acknowledged that complementary and alternative medicines are widely used by heart failure patients but warned that there is limited scientific evidence to support their efficacy.

Ustekinumab is a human monoclonal antibody targeting the cytokines interleukin (IL)-12 and IL-23, which play a rule in the inflammatory and immune responses.

Approximately 75% of adults trust their physicians, nurses, and pharmacists either a great deal or a lot, highlighting the importance of pharmacists for patient education.

Karen Merrill discusses her experiences in pharmacy with plans to celebrate her niece, a first-year pharmacist.

MDL-101 is a proposed novel precision medicine that targets the LAMA1 gene, causing LAMA2 congenital muscular dystrophy type 1a.

The guidelines mark a shift in practice by recommending a multimodal approach to opioid prescribing practices.

There was a detrimental relationship between COVID-19 caseload and mortality observed across multiple types of hospitals.

C. diff survivor and Peggy Lillis Foundation Board Member Maryann Webb discusses how her experience with the infection encouraged her to advocate for patients who are struggling to advocate for themselves.

Poorer prognosis was linked to factors such as reduced hemoglobin levels and advanced stage at diagnosis.

The survey demonstrated that adolescents and young adults (AYAs) who preferred health care professionals (HCPs) as sources of information had sufficient knowledge of contraception options available.

Although the investigators commonly detected treatment-emergent resistant variants, they were rare and transient in nature.

Brooke Peters, PharmD, BCOP, discusses a study conducted at American Oncology Network (AON) to evaluate luspatercept dosing for patients with low- to intermediate-risk myelodysplastic syndromes (MDS).